Wells Fargo
ELVN icon

Wells Fargo’s Enliven Therapeutics ELVN Stock Holding History

Wells Fargo’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.98M Buy
39,079
+24,788
+173% +$1.05M ﹤0.01% 3619
2026
Q1 		$560K Sell
14,291
-28,765
-67% -$797K ﹤0.01% 4095
2025
Q4 		$663K Buy
43,056
+17,232
+67% +$343K ﹤0.01% 4267
2025
Q3 		$529K Buy
25,824
+9,168
+55% +$185K ﹤0.01% 4268
2025
Q2 		$334K Sell
16,656
-1,057
-6% -$20K ﹤0.01% 4429
2025
Q1 		$349K Buy
17,713
+1,047
+6% +$22.5K ﹤0.01% 4332
2024
Q4 		$375K Buy
16,666
+5,548
+50% +$144K ﹤0.01% 4378
2024
Q3 		$284K Sell
11,118
-371
-3% -$8.59K ﹤0.01% 4349
2024
Q2 		$268K Buy
11,489
+3,274
+40% +$68.9K ﹤0.01% 4315
2024
Q1 		$145K Buy
8,215
+1,057
+15% +$16.2K ﹤0.01% 4671
2023
Q4 		$99.1K Buy
7,158
+1,418
+25% +$17.3K ﹤0.01% 4906
2023
Q3 		$78.4K Sell
5,740
-3,130
-35% -$52.7K ﹤0.01% 4924
2023
Q2 		$181K Buy
8,870
+8,846
+36,858% +$179K ﹤0.01% 4638
2023
Q1 		$526 Hold
24
– – ﹤0.01% 6546
2022
Q4 		$397 Hold
24
– – ﹤0.01% 6443
2022
Q3 		$0 Buy
24
+3
+14% +$18 ﹤0.01% 6814
2022
Q2 		$0 Buy
21
+1
+5% +$5 ﹤0.01% 6962
2022
Q1 		$0 Hold
20
– – ﹤0.01% 7227
2021
Q4 		$0 Hold
20
– – ﹤0.01% 7346
2021
Q3 		$0 Buy
20
+12
+150% +$249 ﹤0.01% 7074
2021
Q2 		$0 Sell
8
-576
-99% -$17.9K ﹤0.01% 7004
2021
Q1 		$20K Sell
584
-383
-40% -$19.5K ﹤0.01% 6150
2020
Q4 		$85K Buy
967
+562
+139% +$47.2K ﹤0.01% 5418
2020
Q3 		$33K Sell
405
-285
-41% -$25.7K ﹤0.01% 5635
2020
Q2 		$76K Buy
+690
New +$77.2K ﹤0.01% 5348

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Wells Fargo's ELVN Position: Q2 2026 in Review

Wells Fargo increased its Enliven Therapeutics (ELVN) stake by 173% in Q2 2026, buying an estimated $1.05M and bringing the position to 39,079 shares worth $1.98M. The position accounts for ﹤0.01% of the portfolio, ranked #3619.

Wells Fargo first reported a position in ELVN in Q2 2020 and has held it in 25 quarters since. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Wells Fargo held 39,079 shares of Enliven Therapeutics worth $1.98M as of Q2 2026.
  • Wells Fargo bought 24,788 Enliven Therapeutics shares in Q2 2026, an estimated $1.05M.
  • Enliven Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #3619 holding.
  • Wells Fargo first reported a position in Enliven Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.